Every material Form 8-K NovoCure Ltd has filed with the SEC since September 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Novocure said it received a Not Approvable Letter from the U.S. Food and Drug Administration for its Premarket Approval application for Optune Mya, which treats adult patients with brain metastases from non-small cell lung cancer after stereotactic radiation. The FDA said uncertainty about the degree of clinical benefit prevented approval, and the company said it has no assurance that further discussions or submissions will lead to approval.
The FDA's Not Approvable Letter cites uncertainty around the degree of clinical benefit provided by Optune Mya.
The FDA did not raise concerns about the device's safety profile.
Novocure plans to meet with the FDA to see whether any options could support approval without additional clinical studies.
The filing gives no timeline for those discussions and no assurance of approval.
Novocure reported third quarter 2026 net revenues of $193.4 million, up 16% from a year earlier, and a net loss of $10.4 million, or $0.09 per share, narrowed from $37.3 million a year earlier. The company raised its full-year 2026 guidance for net revenue and adjusted EBITDA, which gives shareholders a higher outlook than before the quarter.
Q3 2026 net revenues were $193.4 million, up 16% year over year, driven by 19% global active patient growth.
Net loss was $10.4 million ($0.09 per share) versus $37.3 million ($0.33 per share) in Q3 2025; adjusted EBITDA was $15.7 million versus a $3.0 million loss.
2026 net revenue guidance was raised to $736 million to $743 million from $710 million to $725 million.
2026 adjusted EBITDA guidance was raised to $24 million to $34 million from $0 million to $15 million.
Japan's Ministry of Health, Labour and Welfare approved Optune Pax for adults with unresectable locally advanced pancreatic cancer, used with gemcitabine and nab-paclitaxel. The approval is based on the Phase 3 PANOVA-3 trial, which met its primary endpoint of statistically significant improvement in median overall survival, and it extends the device's regulatory approvals to another market.
Approval was first announced in a September 15, 2026 press release; the October 1, 2026 exhibit repeats it.
PANOVA-3 showed a statistically significant improvement in median overall survival for patients treated with TTFields.
Optune Pax was previously approved by the U.S. FDA in February 2026 and received a CE Mark in June 2026.
Device-related skin adverse events occurred in 76.3% of Optune Pax-treated participants; 21 (7.7%) had a Grade 3 or higher event.
NovoCure director Timothy Scannell has retired from the board, and his seat was vacated effective September 2, 2026. The filing says the retirement after five years of service did not result from any disagreement with the company or its management.
Timothy Scannell, a director for five years, retired from the board effective September 2, 2026.
The filing states the retirement was not due to any disagreement with the company or management.
The filing contains no replacement director or new appointment.
Form 8-K was filed September 9, 2026, signed by CFO Christoph Brackmann.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every NovoCure Ltd filing is on SEC EDGAR ↗. 8-K briefs of other companies →